Sclerosis of gross cysts of the breast: a three-year study

Breast cysts can be separated into two types: Type I cyst with a lining epithelium which shows apocrine metaplasia, and Type II cyst with an epithelium which is markedly attenuated or absent. The risk of subsequent breast cancer among patients with Type I cysts can be up to 4. The standard treatment is fine needle aspiration, but 20% of the cysts recur. Pharmacological treatment has been tried, which reduces size and volume, but has side-effects and a high recurrence rate post-treatment occurs. The objectives of this prospective study were to sclerose the cyst, induce its regression and prevent or reduce recurrence rate, with the administration of a sclerosing solution (Sclerovein) within the cyst post-aspiration. Fifty-seven patients were followed in the study, 37 with Type I cysts and 20 with Type II cysts. At the end of six months all patients with Type II cysts had no detectable cyst. On the other hand, two patients still had a residual Type I cyst. At the end of three years our recurrence rate appears to be less than 2%, with one patient with a possible recurrence. No significant side-effects were observed. The use of Sclerovein is a simple and safe alternative in the treatment of recurring cysts.

Gross cysts; Cysts, Breast, Sclerosis; Fine needle aspiration

[1] Dupont W. D., Page D. L.: "Risk factors for breast cancer in women with proliferative breast disease". N. Engl. J. Med., 1985, 312, 146.

[2] Page D. L., Dupont W. D., Rogers L. W. et al.: "Atypical hyperplastic lesions of the female breast: a long-term follow-up study". Cancer, 1985, 55, 2698.

[3] Consensus Meeting: "Is'fibrocystic disease'of the brast pre-cancerous?". Arch. Pathol. Lab. Med., 1986, 110, 171.

[4] Haagensen C. D., Bodian C., Haagensen D. E.: " Breast Carcinoma: Risk and Detecion". Philadelphia WB Saunders, 1981, 55.

[5] Azzopardi J. B.: "Problems in Breast Pathology". Philadelphia WB Saunders, 1979, 92.

[6] Dixon J.M., Miller W.R., Scott W. N., F orrest A. P.:'The morphological basis of human breast cyst populations". Br. Med. J., 1984, 288, 275.

[7] Dixon J.M., Miller W. R., Scott W. N.: "Subpopulations of human breast cyst fluid as defined by sodium, potassium and dehydroepiandrosterone content". Arch. Surg., 1982, 357, 195.

[8] Dogliotti L., Orlandi F., Torto M. et al.: "Cations and dehydroepiandrosterone sulphate in cyst fluid of pre- and menopausal patients with gross cystic disease of the breast. Evidence for the existence of subpopulations of cysts". Eur. J. Cancer Clin. Oneal., 1986, 22, 1301.

[9] Miller W.R., Dixon J.M., Scott W. N., Forrest P. M.: "Classification of human breast cysts according to electrolyte and androgen conjugate composition". Clin. Oneal., 1983, 9, 227.

[10] Secreto G., Recchione C., Bellerini P. et al.: "Accumulation of active androgens in breast cyst fluids". Eur. J. Cancer, 1991, 27(1), 44.

[11] Lai L. C., Ghilchic M. W., Shaikg N. A. et al.: "Relationship between epidermal growth factor and dehydroepiandrosterone and its sulphate in breast cyst fluid". Br. J. Cancer, 1988, 60 (3), 320.

[12] Zanardi S., Valenti G., Torrisi R. e col.: "Identification of breast cyst subpopulations: biochemical and morphological features". Cancer Detect. Prev., 1991, 15 (4), 273.

[13] Nahoul K., Kottler M. L.: "Relationships between androgen and estrogen sulfates in breast cyst fluid'. Clin. Chem. Acta, 1992, 31, 209 (3), 179.

[14] Leis H.P.: "Gross breas cysts: significance of apocrine type, identification by cyst fluid analysis, and management". Breast Dis., 1989, 1, 277.

[15] Roberts M. M., Jones V., Elton R. A. et al.: "Risk of breast cancer in women with a history of benign disease of the breast". Br. Med. J., 1984, 288, 275.

[16] Black M. T., Barklay B., Cutler B. et al.: "Association of atypical characteristics of benign breast lesions in the subsequent risk of breast cancer". Cancer, 1972, 29, 338.

[17] Cancer Committee of the College of American Pathologists: Consensus Meeting: is " fibrocystic disease" of the breast precancerous?. Arch. Pathol. Lab. Med., 1986, 110, 171.

[18] Ciato S., Biggeri A., Rosselli T. M. et al.: "Risk of breast cancer subsequent to proven gross cystic disease". Eur. J. Cancer, 1990, 26, 5, 555.

[19] Devitt J.E., To T., Miller A. B.: "Risk of breast cancer in women with breast cysts". Can. Med. Assoc. J., 1992: 1, 147, 45-9.

[20] Dixon J.M., Scott W. N., Miller W.R.: "Natural history of cystic disease: the importance of cyst type". Br. J. Surg., 1985, 72, 1990.

[21] Mauvais-Jarvis P., Kuttenn F.: " Benign breast disease". Curr. Ther. Endocrinol. Metab., 1994, 5, 364-70.

[22] Hockenberger S. J.: "Fibrocystic breast disease: every woman is at risk". Plast. Surg. Nurs., 1993, 13(1), 37.

[23] Hurst J. L., Mega J. F., Hogg J.P.: "Tamoxifen-induced regression of breast cysts". Clin. Imaging., 1998; 22(2), 95.

[24] Dyreborg U., Blichert-Toft M., Boegh L., Kiaer H.: "Needle puncture followed by pneumocystography of palpable breast cysts: a controlled clinical trial". Acta. Radio/., 1985, 26, 277.

[25] Ikede D. M., Helvie M.A., Adler D. D. et al.: "The role of fine needle aspiration and pneumocystography in the treatment of impalpable breast cysts". AJR, 1992, 158, 1239.

[26] Tabar L., Pentek Z., Dean P. B.: "The diagnostic and therapeutic value of breast cyst puncture and pneumocystography". Radiology, 1981, 41, 659.

[27] Haagensen C. D. Gross cystic disease. In Haagensen C. D. (ed): "Diseases of the Breast". 3rd ed. Philadelphia: W.B. Saunders, 1986, 250.

[28] Ciatto S., Cariaggi P., Bularesi P.: "The value of routine cytologic examination of breast cyst fluids". Acta. Cytol., 1987, 31, 301.

[29] Smith D. N., Kaelin C. M., Korbin C. D. et al.: "Impalpable breast cysts: utility of cytologic examination of fluid obtained with radiologically guided aspiration". Radiolo gy, 1997, 204(1), 149.

[30] Czernobilsky B.: "Intracystic carcinoma of the female breast". Surg. Gynecol. Obstet., 1967, 127, 93.